HC Wainwright Reiterates Buy Rating for Halozyme Therapeutics (NASDAQ:HALO)
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They currently have a $72.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 28.62% from the company’s previous […]
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They currently have a $72.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 28.62% from the company’s previous […]
